These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21306363)

  • 1. Increasing time costs and copayments for prescription drugs: an analysis of policy changes in a complex environment.
    Domino ME; Martin BC; Wiley-Exley E; Richards S; Henson A; Carey TS; Sleath B
    Health Serv Res; 2011 Jun; 46(3):900-19. PubMed ID: 21306363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Medicaid Policy Changes on Medication Adherence: Differences by Baseline Adherence.
    Amin K; Farley JF; Maciejewski ML; Domino ME
    J Manag Care Spec Pharm; 2017 Mar; 23(3):337-345. PubMed ID: 28230447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The international generalisability of evidence for health policy: A cross country comparison of medication adherence following policy change.
    Sinnott SJ; Whelton H; Franklin JM; Polinski JM
    Health Policy; 2017 Jan; 121(1):27-34. PubMed ID: 27916432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can increases in CHIP copayments reduce program expenditures on prescription drugs?
    Sen B; Blackburn J; Morrisey M; Becker D; Kilgore M; Caldwell C; Menachemi N
    Medicare Medicaid Res Rev; 2014; 4(2):. PubMed ID: 24967148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Health Outcomes and Prescription Drug Copayments in Medicaid.
    Kostova D; Fox J
    Med Care; 2017 May; 55(5):520-527. PubMed ID: 28234755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of copayments with healthcare utilization and expenditures among Medicaid enrollees with a substance use disorder.
    Lazic A; Tilford JM; Davis VP; Brown CC
    J Subst Use Addict Treat; 2024 Jun; 161():209314. PubMed ID: 38369244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Medicaid prescription copayments on use of antipsychotics and other medications in patients with schizophrenia.
    Doshi JA; Li P; Desai S; Marcus SC
    J Med Econ; 2017 Dec; 20(12):1252-1260. PubMed ID: 28792299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of a Medicaid drug copayment program on the utilization and cost of prescription services.
    Nelson AA; Reeder CE; Dickson WM
    Med Care; 1984 Aug; 22(8):724-36. PubMed ID: 6433121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Who bears the burden of Medicaid drug copayment policies?
    Stuart B; Zacker C
    Health Aff (Millwood); 1999; 18(2):201-12. PubMed ID: 10091449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How effective are copayments in reducing expenditures for low-income adult Medicaid beneficiaries? Experience from the Oregon health plan.
    Wallace NT; McConnell KJ; Gallia CA; Smith JA
    Health Serv Res; 2008 Apr; 43(2):515-30. PubMed ID: 18248405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Medicaid copayments on patients with cancer: lessons for Medicaid expansion under health reform.
    Subramanian S
    Med Care; 2011 Sep; 49(9):842-7. PubMed ID: 21577164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity.
    Soumerai SB; Avorn J; Ross-Degnan D; Gortmaker S
    N Engl J Med; 1987 Aug; 317(9):550-6. PubMed ID: 3302713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population.
    Hartung DM; Carlson MJ; Kraemer DF; Haxby DG; Ketchum KL; Greenlick MR
    Med Care; 2008 Jun; 46(6):565-72. PubMed ID: 18520310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing prescribing patterns and increasing prescription expenditures in Medicaid.
    Fink KS; Byrns PJ
    Ann Fam Med; 2004; 2(5):488-93. PubMed ID: 15506586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unintended consequences of a Medicaid prescription copayment policy.
    Lieberman DA; Polinski JM; Choudhry NK; Avorn J; Fischer MA
    Med Care; 2014 May; 52(5):422-7. PubMed ID: 24686394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copayment for pharmaceutical services in a Medicaid program.
    Nelson AA; Quick MR
    Contemp Pharm Pract; 1980; 3(1):37-42. PubMed ID: 10297666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic impacts of Medicaid in North Carolina.
    Dumas C; Hall W; Garrett P
    N C Med J; 2008; 69(2):78-87. PubMed ID: 18605153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication days' supply, adherence, wastage, and cost among chronic patients in Medicaid.
    Taitel M; Fensterheim L; Kirkham H; Sekula R; Duncan I
    Medicare Medicaid Res Rev; 2012; 2(3):. PubMed ID: 24800150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.
    Rome BN; Feldman WB; Desai RJ; Kesselheim AS
    JAMA Netw Open; 2021 May; 4(5):e218816. PubMed ID: 33944925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans.
    Fischer MA; Avorn J
    Health Serv Res; 2003 Aug; 38(4):1051-63. PubMed ID: 12968816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.